However, there have been no benefits in terms of reduced mortality, the ministry said. "It (remdesivir) has to be used with extreme caution due to its potential for serious adverse effects including liver and kidney injury. Similarly, for tocilizumab studies have not shown any benefits in mortality reduction, the statement said. "However, if used for patients with severe conditions, proper informed consent is required. Rampant use is to be discouraged since the effect of the drug is directed at the ' cytokine storm ', it said.

Source: Economic Times July 11, 2020 23:43 UTC